Natural killer cells combined with a bispecific antibody induced response among nearly 90% of patients with relapsed or refractory CD30-positive lymphoma, according to phase 1/phase 2 trial results.
All patients who received the recommended phase 2 dose of the investigational therapy achieved objective response, findings presented at American Association for Cancer Research Annual Meeting showed.
Patients with CD30-positive lymphomas who do not respond to standard therapies eventually will experience disease progression as their tumors become resistant to treatment, according to Yago L. Nieto,